Patents by Inventor Samuel GAVARD MOLLIARD

Samuel GAVARD MOLLIARD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11382853
    Abstract: The present invention generally relates to hyaluronic acid-based compositions for aesthetic use, and more specifically to a dermal filler composition comprising hyaluronic acid crosslinked with citric acid or a salt thereof. Furthermore, the present invention relates to a method for preparing said dermal filler composition and its use for aesthetic purposes, in particular for skin rejuvenation and correction of fine lines.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: July 12, 2022
    Assignee: ANTEIS S.A.
    Inventors: Karine Mondon, Samuel Gavard Molliard
  • Patent number: 10493006
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between 5% and 60% (mass/volume), said hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; said injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: December 3, 2019
    Assignee: ANTEIS S.A.
    Inventor: Samuel Gavard Molliard
  • Patent number: 10463762
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 0.1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between 5% and 60% (mass/volume), the hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; the injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 5, 2019
    Assignee: ANTEIS S.A.
    Inventor: Samuel Gavard Molliard
  • Patent number: 10434040
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 0.1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between more than 70% and 140% (mass/volume), said hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; said injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: October 8, 2019
    Assignee: ANTEIS S.A.
    Inventor: Samuel Gavard Molliard
  • Publication number: 20190269597
    Abstract: The present invention generally relates to hyaluronic acid-based compositions for aesthetic use, and more specifically to a dermal filler composition comprising hyaluronic acid crosslinked with citric acid or a salt thereof. Furthermore, the present invention relates to a method for preparing said dermal filler composition and its use for aesthetic purposes, in particular for skin rejuvenation and correction of fine lines.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 5, 2019
    Inventors: Karin MONDON, Samuel GAVARD MOLLIARD
  • Patent number: 10272181
    Abstract: The object of the present invention is a method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine hydrochloride and an alkaline agent, sterilized with heat, having hyaluronic acid concentration and flow properties, equivalent to those of the corresponding hydrogel based on hyaluronic acid not containing any lidocaine hydrochloride. The present invention also relates to various uses of the aforementioned hydrogel.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 30, 2019
    Assignee: ANTEIS S.A.
    Inventor: Samuel Gavard Molliard
  • Publication number: 20180221255
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 0.1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between more than 70% and 140% (mass/volume), said hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; said injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventor: Samuel GAVARD MOLLIARD
  • Patent number: 10028976
    Abstract: A sterile injectable aqueous formulation in the form of a gel made up of hyaluronic acid or a salt thereof and one or more polyols is provided. The gel formulation can be applied to the intra-articular area in the treatment of joint degeneration and osteoarthritis. The gel formulation has a rheology similar to that of synovial liquid and has an elevated resistance to degradation due to the synergistic action between the hyaluronic acid and the polyols.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: July 24, 2018
    Assignee: APTISSEN SA
    Inventors: Samuel Gavard Molliard, Olivier Benoit
  • Publication number: 20180193232
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between 5% and 60% (mass/volume), said hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; said injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Application
    Filed: March 6, 2018
    Publication date: July 12, 2018
    Inventor: Samuel GAVARD MOLLIARD
  • Patent number: 9623150
    Abstract: An injectable hydrogel, includes, in weight, in a physiologically acceptable carrier fluid: 0.01 to 5% of glycerol and 0.1 to 5% of cross-linked hyaluronic acid, or one of the salts thereof; characterized in that the hyaluronic acid or one of the salts thereof is cross-linked by the formation of covalent bonds using bifunctional or polyfunctional molecules, the injectable hydrogel being sterilized in moist heat and having viscoelastic properties such that Tan ? at a frequency of 1 Hz is less than or equal to 1.10. A method for producing the hydrogel, to a kit containing the hydrogel, as well as to the use thereof in dermatology are also described.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: April 18, 2017
    Assignee: ANTEIS S.A.
    Inventors: Samuel Gavard Molliard, Cyrille Vinchon
  • Publication number: 20170065741
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 0.1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between 5% and 60% (mass/volume), the hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; the injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventor: Samuel GAVARD MOLLIARD
  • Publication number: 20160228613
    Abstract: The object of the present invention is a method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine hydrochloride and an alkaline agent, sterilized with heat, having hyaluronic acid concentration and flow properties, equivalent to those of the corresponding hydrogel based on hyaluronic acid not containing any lidocaine hydrochloride. The present invention also relates to various uses of the aforementioned hydrogel.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 11, 2016
    Applicant: ANTEIS S.A.
    Inventor: Samuel GAVARD MOLLIARD
  • Publication number: 20150352143
    Abstract: A sterile injectable aqueous formulation in the form of a gel made up of hyaluronic acid or a salt thereof and one or more polyols is provided. The gel formulation can be applied to the intra-articular area in the treatment of joint degeneration and osteoarthritis. The gel formulation has a rheology similar to that of synovial liquid and has an elevated resistance to degradation due to the synergistic action between the hyaluronic acid and the polyols.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 10, 2015
    Inventors: Samuel GAVARD MOLLIARD, Olivier BENOIT
  • Patent number: 9138405
    Abstract: A sterile injectable aqueous formulation in the form of a gel is made up of hyaluronic acid (or one of the salts thereof) with or without other natural polysaccharide(s) and one or more polyols. The formulation is of intra-articular application in the treatment of joint degeneration, in some cases having a rheology similar to that of synovial liquid and always with an elevated resistance to degradation due to a synergistic action between the hyaluronic acid and the polyols.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: September 22, 2015
    Assignee: APTISSEN SA
    Inventors: Samuel Gavard Molliard, Olivier Benoit
  • Publication number: 20150257989
    Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between 5% and 60% (mass/volume), the hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; the injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.
    Type: Application
    Filed: September 24, 2013
    Publication date: September 17, 2015
    Inventor: Samuel Gavard Molliard
  • Publication number: 20150238525
    Abstract: This invention relates to an absorbable sterile injectable aqueous formulation that is ready to use, used for therapeutic purposes as a cohesive particle-based viscoelastic gel containing i) cross-linked hyaluronic acid, or one of its salts, at a concentration between 1% and 4% (mass/volume), with the cross-linking that is performed making it possible to obtain a gel having a base of cross-linked hyaluronic acid having a so-called cohesive structure, and ii) hydroxyapatite. at a concentration between 10% and 70% (mass/volume), said hydroxyapatite being in the form of particles having an average size less than or equal to 650 ?m; with the said sterile injectable aqueous formulation having viscoelastic properties such that Tan ? at a frequency of 1 Hz is less than or equal to 0.60.
    Type: Application
    Filed: September 24, 2013
    Publication date: August 27, 2015
    Applicant: APTISSEN S.A.
    Inventor: Samuel Gavard Molliard
  • Publication number: 20140038917
    Abstract: The present invention relates generally to the treatment and/or prevention of pain associated with an intra-articular joint degeneration or disease. This invention concerns in particular a sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint of a subject, in the form of a gel.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 6, 2014
    Applicant: ANTEIS S.A.
    Inventors: Samuel Gavard Molliard, Olivier Benoit
  • Patent number: 8574629
    Abstract: An injectable hydrogel includes a hydrogel matrix based on (a) single-phase-type cross-linked biopolymer(s), characterized in that previously cross-linked biopolymer hydrogel particles are co-cross-linked with the matrix. A method of and a process for production of the above-mentioned hydrogel are also disclosed.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: November 5, 2013
    Assignee: Anteis S.A.
    Inventor: Samuel Gavard Molliard
  • Publication number: 20130274224
    Abstract: The present invention relates to an intraocularly injectable sterile aqueous formulation based on a mixture of hyaluronic acid and alginate, or a salt thereof, used in ophthalmology and having specific viscoelasticity, spreading, covering and ocular tissue adhesion properties and also a high capacity for neutralizing free radicals, said properties enabling said composition to strongly protect the eye tissues.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 17, 2013
    Applicant: ANTEIS S.A.
    Inventor: Samuel Gavard Molliard
  • Patent number: 8455465
    Abstract: An injectable aqueous composition of hyaluronic acid or one of the salts thereof, one or more polyol(s) and lidocaine is used for cosmetic purposes or for therapeutic purposes. It has improved viscoelastic rheological properties and long in vivo persistence. The polyol is chosen, for example, from glycerol, sorbitol, propylene glycol, mannitol, erythritol, xylitol, maltitol and lactitol. The particular properties are obtained by heat sterilizing the mixture.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: June 4, 2013
    Assignee: Anteis S.A.
    Inventor: Samuel Gavard Molliard